===
ABIVAX
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
07-May-2024 / 22:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Annual ordinary and extraordinary general meeting of May 30, 2024
Availability of the preparatory documents
PARIS, France, May 7, 2024, 10:00PM CEST - Abivax SA (Euronext Paris & Nasdaq: ABVX) ("Abivax" or the "Company"), a
clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory
mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders
that its ordinary and extraordinary general meeting (the "General Meeting") will be held on May 30, 2024, at 10:00 am
(CEST), at the offices of Dechert (Paris) LLP, located at 22 rue Bayard in Paris (75008), France.
The preliminary notice of meeting comprising the agenda and the draft resolutions, as well asinformation on how to
attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April
24, 2024 (N°2400962).
The information and preparatory documents for this General Meeting are made available to the Company's shareholders in
accordance with the procedures and within the time limits provided for by the applicable legal and regulatory
provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the
Company's website:www.abivax.com
Any shareholder wishing to receive these documents by post or electronically may make a request until midnight, Paris
time, on May 25, 2024 (i.e., the fifth day before the General Meeting) by contacting the Company. For bearer
shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an
intermediary, in accordance with Article L. 211-3 of the French Monetary and Financial Code.

About Obefazimod
Obefazimod, Abivax's lead investigational drug candidate, is an orally administered small molecule that was
demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients
with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program
(ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical
trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC
is ongoing.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural
regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France
and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the
treatment of moderately to severely active ulcerative colitis. More information on the Company is available at
www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @Abivax.
Contact:

Abivax Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878

Abivax Communications
communications@abivax.com

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, forecasts and estimates, including those relating to the
Company's business and financial objectives. Words such as "design," "expect," "forward," "future," "potential,"
"plan," "project" and variations of such words and similar expressions are intended to identify forward-looking
statements. Although Abivax's management believes that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks,
contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax,
that could cause actual results and developments to differ materially from those expressed in, or implied or projected
by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can
be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal
obligations including its universal registration document (Document d'Enregistrement Universel) and in our Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption "Risk
Factors." These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in
research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and
other matters that could affect the availability or commercial potential of such product candidates. Special
consideration should be given to the potential hurdles of clinical and pharmaceutical development including further
assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements,
forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue
reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking
statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products (including products currently in development) that is
included in this press release is not intended to constitute an advertisement. This press release is for information
purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of
an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should
not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or
specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own
judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be
restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform
themselves about and to observe any such restrictions.
Regulatory filing PDF file

File: 240507_Abivax_PR_AGM_Availability of Documents  
Language:        English 
Company:         ABIVAX 

5, Rue de La Baume
75008 Paris
France

E-mail:          info@abivax.de 
Internet:        www.abivax.de 
ISIN:            FR0012333284 

Euronext Ticker: ABVX

AMF Category:    Inside information / Other releases 
EQS News ID:     1897745 

End of Announcement EQS News Service
===
1897745 07-May-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1897745&application_name=news

END) Dow Jones Newswires

May 07, 2024 16:00 ET (20:00 GMT)